PF-543 (also called PF543; PF 543; Sphingosine Kinase 1 Inhibitor II) is a novel cell-permeable and sphingosine-competitive inhibitor of SphK1 with potential antitumor activity.

JTE-013 HCl is a novelm potent, selective antagonist of sphingosine-1-phosphate 2 (S1P2) receptor, with IC50 of 17 and 22 nM, respectively, (IC50 >10 µM for for binding to human S1P1 and S1P3).

Opaganib (formerly known as ABC294640; ABC-294640; Trade name Yeliva) is a novel, potent, selective, competitive and orally bioavailable aryladamantane analog and selective sphingosine kinase-2 (SphK2) inhibitor with potential anticancer activity.

Ponesimod (formerly known as ACT-128800; ACT128800; Ponvory) is an orally bioavailable and selective agonist of sphingosine-1-phosphate receptor 1 (S1PR1, S1P1) approved in 2021 by FDA to treat relapsing forms of multiple sclerosis.

CAY10444 (BML-241; CAY-10444) is a novel and potent S1P3 (shingosine-1-phosphate receptor) specific antagonist.

PF429242 (PF-429242) is a novel, potent, reversible and competitive S1P [sterol regulatory element-binding protein (SREBP) site 1 protease] inhibitor with an IC50 of 170 nM.

Phorbol 12-myristate 13-acetate (PMA) is a novel and potent protein kinase C (PKC) agonist with the potential for the treatment of acute myeloid leukemia and cardiac fibrosis.

SKI II (also known as SphK-I2; Sphingosine kinase inhibitor II; SK-III) is a potent, highly selective, non-lipid and non-ATP-competitive sphingosine kinase (SphK) inhibitor with potential anticancer activity.

Siponimod (BAF-312; WHO-9491; NVP-BAF-312; Mayzent) is a novel, potent and orally bioavailable S1P receptor modulator with immunomodulating activity.

Fingolimod HCl (formerly FTY-720; FTY 720; Gilenia and Gilenya), an FDA approved drug for the treatment of Multiple sclerosis, is a S1P (sphingosine 1-phosphate) antagonist with potential antineoplastic activity.